glp-1 vs metformin New aspects of an old drug: as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser | Diabetologia Glucagon-Like Peptide-1 Based Therapies: A

Find your perfect match

As a dietary supplement, the quality can also vary by batch

Consequently, optimization of the strategies for more precise targeting of astrocytes, microglia, and neurons is much needed to develop the best possible therapies with the least neurotoxicity (90)

PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs